Filing Details
- Accession Number:
- 0001818382-24-000185
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-11 17:52:09
- Reporting Period:
- 2024-09-09
- Accepted Time:
- 2024-09-11 17:52:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1818382 | Humacyte Inc. | HUMA | Biological Products, (No Disgnostic Substances) (2836) | 851763759 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1878020 | W Brady Dougan | 2525 East North Carolina Highway 54 Durham NC 27713 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-09-09 | 157,704 | $5.42 | 3,519,558 | No | 4 | S | Indirect | By Ayabudge LLC |
| Common Stock | Disposition | 2024-09-10 | 288,674 | $5.23 | 3,230,884 | No | 4 | S | Indirect | By Ayabudge LLC |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Ayabudge LLC |
| No | 4 | S | Indirect | By Ayabudge LLC |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 510,161 | Direct | |
| Common Stock | 242,054 | Indirect | By spouse |
| Common Stock | 1,148,240 | Indirect | By The Niklason Living Trust |
Footnotes
- The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.
- The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.36 to $5.505. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.14 to $5.325. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
